Ottobock announces resolved IP litigation with Cranial Technologies

AUSTIN, Texas, [September 15, 2026] — Ottobock announced today that it has resolved its IP litigation with Cranial Technologies through a settlement agreement on mutually acceptable, confidential terms. 

Ottobock removed the MyCRO Band cranial helmet product from its U.S. portfolio. As part of the settlement agreement, Ottobock has agreed not to produce such devices in the U.S., including 3D printed cranial orthotic devices. Ottobock has agreed to pay a settlement fee to Cranial Technologies. 

The settlement does not constitute, and should not be construed as, an admission of liability or wrongdoing by Ottobock. 

Ottobock remains committed to serving clinicians and patients through innovative prosthetic and orthotic solutions aligned with its long-term strategic priorities. 

About Ottobock 

Ottobock, a listed global MedTech champion, combines over 100 years of tradition with outstanding innovative strength in the fields of prosthetics, neuro-orthotics and exoskeletons. Ottobock develops innovative fitting solutions for people with limited mobility and is driving the digitalization of the industry. Founded in Berlin in 1919, the company has business activities in 45 countries with nearly 9,300 employees (FTEs) worldwide and operates the largest international patient care network with around 420 patient care clinics. Ottobock is shaping the future of human bionics with a strong R&D ratio in the products and components business and over 2,600 patents and patent applications. Ottobock’s mission of improving freedom of movement, quality of life and independence is deeply rooted in the company's DNA, as is its social commitment: Ottobock has been a partner and supporter of the Paralympics since 1988.